Ignite Proteomics, a subsidiary of IMAC Holdings, has announced a one-year collaboration with Vanderbilt University Medical Center (VUMC) aimed at enhancing the understanding of how breast cancer cells avoid detection by the immune system. This partnership will utilize VUMC’s clinical samples to characterize specific protein-signaling pathways associated with breast tumors.
As part of the collaboration, VUMC will supply tumor tissue samples from patients undergoing chemotherapy and immunotherapy. Ignite Proteomics will conduct specialized analyses of these samples to identify key immune and signaling biomarkers that could guide treatment decisions for breast cancer patients.
Faith Zaslavsky, President and CEO of Ignite Proteomics, stated, “Partnering with VUMC’s world-class immuno-oncology team allows us to deploy our RPPA platform on rigorously annotated clinical samples.” Dr. Justin Balko, Principal Investigator at VUMC, noted that the study offers insights into tumor-immune interactions and aims to enhance immunotherapy strategies.
This collaboration highlights the ongoing need for multi-dimensional approaches to cancer treatment, as current immunotherapies do not always work effectively for all patients. By developing better biomarkers, the partnership seeks to improve the precision of cancer treatments.
The primary source was GlobeNewswire.
